FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to oncology, and can be used to determine the therapeutic approach to the patients with metastatic forms and recurrent triple-negative breast cancer (TNBC). Concentration of cells expressing markers CD36+CD163+CD206+, LIN-HLADR-CD33+CD66b-CD14+CD15- is determined in the tumour microenvelopment. Blood concentration of gamma/delta T-lymphocytes is determined. Level of spontaneous production of TNF-α and TGF-β is determined in lymphocyte culture. Derived values are used to calculate the discriminant functions F1, F2 and F3. Therapeutic approach is determined by the highest value of one of the functions.
EFFECT: method provides the effective determination of the therapeutic approach in the patients with metastatic forms and recurrent TNBC by creating an algorithm which enables to select the most effective method of treatment from alternative versions.
1 cl, 9 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING THE DURATION OF A RELAPSE-FREE PERIOD IN PATIENTS WITH RESECTABLE THRICE-NEGATIVE BREAST CANCER | 2021 |
|
RU2780922C1 |
| METHOD OF PREDICTING THE DEVELOPMENT OF METASTASES IN PATIENTS WITH UNRESECTABLE TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2802141C1 |
| METHOD FOR ASSESSING THE SENSITIVITY OF A TUMOR TO IMMUNO-ONCOLOGICAL DRUGS | 2021 |
|
RU2771760C1 |
| METHOD FOR PREDICTION OF LIFE EXPECTANCY IN PATIENTS WITH METASTATIC TUMORS | 2023 |
|
RU2821659C1 |
| METHOD OF ASSESSING IMMEDIATE RESULTS OF TREATMENT OF PATIENTS WITH DISSEMINATED FORMS OF MALIGNANT TUMORS | 2023 |
|
RU2806483C1 |
| METHOD FOR TREATING THRICE-NEGATIVE BREAST CANCER | 2017 |
|
RU2757905C2 |
| THERAPY OF METASTATIC UROTHELIAL CANCER USING ANTIBODY-DRUG CONJUGATE SATSITUZUMAB GOVITECAN (IMMU-132) | 2017 |
|
RU2757395C2 |
| METHOD FOR PREDICTING THE EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER | 2019 |
|
RU2715551C1 |
| METHOD FOR PREDICTION OF SURVIVAL RATE IN PATIENTS WITH LUNG ADENOCARCINOMA CARRYING A MUTATION IN THE KRAS GENE | 2019 |
|
RU2702986C1 |
| METHOD FOR COMBINED TREATMENT OF RESECTABLE LOCALLY ADVANCED GASTRIC CANCER WITH PERITONEAL CARCINOMATOSIS APPLYING PERSONALISED SYSTEMIC AND INTRAPERITONEAL CHEMOTHERAPY | 2021 |
|
RU2773100C1 |
